Am J Transplant, Volume 20, Suppl 3 Archives - Page 47 of 223 - ATC Abstracts

2020 American Transplant Congress
Association of Congenital Anomalies of the Kidney and Urinary Tract with Urinary Tract Infection and Graft Rejection in Pediatric Kidney Transplant Recipients
M. Bock, D. Han, A. Sikora, K. Mckinnon, S. Hecht, M. Chandran, V. Vemulakonda
Children's Hospital Colorado, Denver, CO
*Purpose: Congenital anomalies of the kidney and urinary tract (CAKUT) are a leading cause of pediatric end-stage renal disease (ESRD). Prior studies have shown an…
2020 American Transplant Congress
Kidney Transplant Recipient Outcomes from Older (60+) Hypertensive Living Donors
A. Sharfuddin, T. Taber, O. Adebiyi, M. Panezai, D. Mishler, M. Yaqub
Indiana University School of Medicine, Indianapolis, IN
*Purpose: Although the data supporting long-term safety of nephrectomy in hypertensive donors has been reported, there is scarcity of long term data on the recipient…
2020 American Transplant Congress
Lymphoceles in Kidney Transplant Recipients: Incidence, Risk Factors, Outcomes, and Clinical Management
J. Kim, E. Nguyen, M. Minkovich, O. Famure, Y. Li, J. Lee
Toronto General Hospital, Toronto, ON, Canada
*Purpose: Post kidney transplantation, lymphocele development can result in morbidity for the patient and graft. Lacking prior studies in a representative cohort, we aimed to…
2020 American Transplant Congress
The Association between Infection and Important Clinical Outcomes in Acute-On-Chronic Liver Patients Admitted to ICU: A Single Center Cohort Analysis
M. Kim¹, A. Pawlowski², R. G. Wunderink³, D. P. Ladner⁴, C. J. Karvellas⁵
¹Neurology, Northwestern University, Chicago, IL, ²Northwestern University, Chicago, IL, ³Medicine, Northwestern University, Chicago, IL, ⁴Surgery, Northwestern University, Chicago, IL, ⁵Medicine, University of Alberta, Edmonton, AB, Canada
*Purpose: One of the most common precipitants of acute on chronic liver failure (ACLF) in cirrhotic patients is sepsis. We aimed to evaluate the relationship…
2020 American Transplant Congress
Evaluation of Rejection, Infection, and Malignancy Outcomes in Elderly Liver Transplant Recipients Compared to a Younger Cohort
B. Almalki¹, K. Cunningham¹, C. D'Agostino¹, M. Kapugi¹, C. Kane¹, A. Novak¹, D. Ladner², J. Schulte¹
¹Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ²Division of Transplant Surgery, Northwestern Memorial Hospital, Chicago, IL
*Purpose: Previous data has shown elderly liver transplant recipients (LTx) to be at a lower risk of acute rejection than younger recipients. As such, elderly…
2020 American Transplant Congress
Outcomes Following Deceased Donor Split/Partial Liver Transplant for Hepatocellular Carcinoma
L. Matsuoka, T. Sutcliffe, I. Feurer, S. Rega, S. Alexopoulos
Vanderbilt University Medical Center, Nashville, TN
*Purpose: To mitigate waiting time for liver transplant for hepatocellular carcinoma (HCC) and increase available organs, partial or split liver transplant (SLT) has been utilized.…
2020 American Transplant Congress
A Three-Decade Analysis of Pancreatic Adenocarcinoma Following Liver Transplantation
O. Y. Mousa¹, J. E. Corral², K. Wijarnpreecha², R. Shah³, V. S. Louwagie⁴, M. J. Bartel⁵, B. Brahmbhatt²
¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Jacksonville, FL, ³Emory University, Atlanta, GA, ⁴Mayo Clinic Health System, Mankato, MN, ⁵Fox Chase Cancer Center, Philadelphia, PA
*Purpose: Liver transplant (LT) recipients are at risk of serious long term complications, including a higher risk of de novo malignancies compared to the general…
2020 American Transplant Congress
Lack of Drug-Drug Interaction between Maribavir and Voriconazole
I. H. Song¹, K. Ilic², J. Wu³
¹Quantitative Clinical Pharmacology, Shire, a Takeda Company, Lexington, MA, ²Rare Disease TAU, Shire, a Takeda Company, Lexington, MA, ³Biostat, Shire, a Takeda Company, Lexington, MA
*Purpose: Maribavir is being evaluated in Phase 3 trials for the treatment of cytomegalovirus infections in transplant recipients. These patients often take numerous concomitant medications,…
2020 American Transplant Congress
Safety and Efficacy of Prophylactic Valganciclovir Dosing after Solid Organ Transplant
K. Gandhi, D. Masic, M. Santarossa, F. Albarillo, N. Clark, G. Reid
Loyola University Medical Center, Maywood, IL
*Purpose: At centers where antiviral prophylaxis is used after solid organ transplant, valganciclovir is administered for the prevention of cytomegalovirus (CMV). At Loyola University Medical…
2020 American Transplant Congress
Contract a Virus to Save a Life: A Comparison of Short Term Outcomes between Adult Hepatitis C Negative Kidney Transplant Recipients Receiving a Hepatitis C NAT Positive versus Hepatitis C Negative Deceased Donor Kidney
H. Schaefer¹, B. Concepcion¹, A. Sudhakar², S. Rega¹, I. Feurer¹, S. Shawar¹, B. Dubrey¹, D. Shaffer¹, R. Forbes¹
¹Vanderbilt University, Nashville, TN, ²Drexel University, Philadelphia, PA
*Purpose: The United States opioid use epidemic over the past decade has coincided with an increase in hepatitis C positive (HCV+) kidney donors. Our aim…